Technical Analysis for RGLS - Regulus Therapeutics Inc.

Grade Last Price % Change Price Change
grade D 0.84 0.31% 0.00
RGLS closed up 0.31 percent on Thursday, September 19, 2019, on 33 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Earnings due: Sep 27

*** please verify all earnings dates ***
1 Watcher
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical RGLS trend table...

Date Alert Name Type % Chg
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 0.31%
Boomer Buy Setup Bullish Swing Setup 0.31%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.31%
Narrow Range Bar Range Contraction 0.31%

Older signals for RGLS ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Read My Charts!
Configure default chart indicators
RGLS Chart by TradingView
Basic chart:
Profile
Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat various diseases in the United States. The company utilizes its microRNA product platform to develop anti-miRs, a chemically modified single-stranded oligonucleotides. Its microRNA development candidates target miR-122 in hepatitis C virus infection; miR-21 and miR-221 in hepatocellular carcinoma; miR-21 in kidney fibrosis; miR-33 in atherosclerosis; and miR-10b in glioblastoma. The company has strategic alliances with AstraZeneca AB, GlaxoSmithKline plc, Sanofi, and Alnylam and Isis, as well as a strategic collaboration with Biogen Idec MA Inc. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.
Biopharmaceutical Diseases Genetics Glioblastoma Regulus Therapeutics Hepatocellular Carcinoma RNA Alnylam Pharmaceuticals Hepatitis C Virus Infection Nucleic Acids Atherosclerosis Microrna
Is RGLS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Sep 12 Regulus Therapeutics Announces Publication in Nature Communications Identifying RGLS4326 as a Potential Promising Treatment for ADPKD
Sep 6 Benzinga's Top Upgrades, Downgrades For September 6, 2019
Sep 6 Cantor likes Durect in premarket analyst action
Sep 3 Regulus Therapeutics to Present at the H.C. Wainwright Global Investment Conference
Aug 29 Regulus Therapeutics to Present at the Wells Fargo Healthcare Conference
Aug 8 Regulus (RGLS) Reports Q2 Loss, Misses Revenue Estimates
Aug 8 Regulus Therapeutics EPS beats by $0.24, misses on revenue
Aug 8 Regulus Therapeutics Reports Second Quarter 2019 Financial Results and Recent Updates
Aug 6 What Percentage Of Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Do Insiders Own?
Aug 1 Will Regulus (RGLS) Report Negative Q2 Earnings? What You Should Know
See more RGLS news...
Indicators
Indicator Value
52 Week High 3.14
52 Week Low 0.5026
Average Volume 155,595
200-Day Moving Average 1.0474
50-Day Moving Average 0.754
20-Day Moving Average 0.6961
10-Day Moving Average 0.7846
Average True Range 0.0746
ADX 31.59
+DI 21.0889
-DI 11.3291
Chandelier Exit (Long, 3 ATRs ) 0.6362
Chandelier Exit (Short, 3 ATRs ) 0.7939000000000001
Upper Bollinger Band 0.892
Lower Bollinger Band 0.5002
Percent B (%b) 0.87
BandWidth 56.285017
MACD Line 0.0364
MACD Signal Line 0.0086
MACD Histogram 0.0278
Fundamentals Value
Market Cap 87.18 Million
Num Shares 104 Million
EPS -1.53
Price-to-Earnings (P/E) Ratio -0.55
Price-to-Sales 450.54
Price-to-Book 2.98
PEG Ratio -0.03
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.88
Resistance 3 (R3) 0.88 0.87 0.88
Resistance 2 (R2) 0.87 0.85 0.87 0.87
Resistance 1 (R1) 0.85 0.85 0.84 0.85 0.87
Pivot Point 0.84 0.84 0.83 0.84 0.84
Support 1 (S1) 0.82 0.83 0.82 0.83 0.81
Support 2 (S2) 0.81 0.82 0.81 0.81
Support 3 (S3) 0.79 0.81 0.80
Support 4 (S4) 0.80